McGee, K.C., et al. (2011) Visfatin is regulated by rosiglitazone in type 2 diabetes mellitus and influenced by NFkappaB and JNK in human abdominal subcutaneous adipocytes. PLoS One, 6, e20287. doi:10.1371/journal.pone.0020287

has been cited by the following article:

• TITLE: Visfatin levels are low in subjects with type 2 diabetes compared to age-matched controls

  AUTHORS: Subhashini Yaturu, Jared Davis, LaTonya Franklin, Runhua Shi, Prasanna Venkatesh, Sushil K. Jain

  KEYWORDS: Visfatin; Adiponectin; Resistin; Diabetes; Insulin Resistance; TNF-α; BMI; Metabolic Syndrome; Visceral Adiposity

  JOURNAL NAME: Journal of Diabetes Mellitus, Vol.2 No.4, November 22, 2012

  ABSTRACT: Background: Visceral adiposity correlates strongly with insulin resistance and components of metabolic syndrome. Visfatin is preferentially produced by human visceral adipose tissue. Objective: The objective of this study was to evaluate the relationship between circulating levels of visfatin and other adipocytokines in patients with type 2 diabetes (DM) compared to the age-matched control subjects without DM. Methods: Anthropometric parameters, lipid profiles, high-sensitivity CRP (hs-CRP), insulin resistance [HOMA-IR], and levels of visfatin, TNF-α, and resistin were evaluated in 55 subjects with diabetes and 56 age matched control subjects without diabetes. Results: The visfatin levels were significantly lower in subjects with diabetes (p